CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Chengdu Easton Biopharmaceuticals Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Chengdu Easton Biopharmaceuticals Co Ltd
No. 8 Ankang Road, Shuangliu District
Phone: +86 2886106668p:+86 2886106668 CHENGDU, SIC  610219  China Ticker: 688513688513
Business Summary
Chengdu Easton Biopharmaceuticals Co Ltd is a China-based company mainly engaged in the research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The Company's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The Company operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board YingWang 56 12/1/2020 12/1/2020
Chief Financial Officer, Director ChangjianXiong 45 2/1/2020 2/1/2020
General Manager, Director MingxuYuan 51 12/1/2020 12/1/2020
11 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,400 (As of 12/31/2023)
Outstanding Shares: 118,998,908 (As of 3/31/2024)
Shareholders: 3,735
Stock Exchange: SHA
Fax Number: +86 2862321999


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024